Details for Patent: 8,618,142

Which drugs does patent 8,618,142 protect, and when does it expire?

Patent 8,618,142 protects DALIRESP and is included in one NDA.

This patent has thirty-seven patent family members in twenty-nine countries.

Summary for Patent: 8,618,142

Title:	Process for the preparation of roflumilast
Abstract:	A composition comprising: roflumilast having a purity of greater than or equal to 99% by weight, and N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-hydroxybenzamide present (relative to roflumilast) in an amount greater than zero and less than 0.1% by weight.
Inventor(s):	Kohl; Bernhard (Constance, DE), Mueller; Bernd (Constance, DE), Palosch; Walter (Rielasingen, DE)
Assignee:	Takeda GmbH (Constance, DE)
Application Number:	13/860,264
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,618,142
Patent Claim Types: see list of patent claims	Composition; Compound; Dosage form; Formulation;

Drugs Protected by US Patent 8,618,142

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astrazeneca	DALIRESP	roflumilast	TABLET;ORAL	022522-002	Jan 23, 2018	AB	RX	Yes	No			Y
Astrazeneca	DALIRESP	roflumilast	TABLET;ORAL	022522-001	Feb 28, 2011	AB	RX	Yes	Yes			Y

Foreign Priority and PCT Information for Patent: 8,618,142

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	03005245	Mar 10, 2003

International Family Members for US Patent 8,618,142

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	043531
Austria	447555
Australia	2004220357
Brazil	PI0406427